Skip to content

High-frequency Oscillatory Ventilation (HFOV) in Preterm Infants With Severe Respiratory Distress Syndrome (RDS)

Principal Investigator

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01496508
Enrollment
360
Registered
2011-12-21
Start date
2007-06-30
Completion date
2011-06-30
Last updated
2011-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome

Keywords

high-frequency oscillatory ventilation, respiratory distress syndrome, preterm infants, neurodevelopment, preterm infants with severe respiratory distress syndrome

Brief summary

Respiratory distress syndrome (RDS) is common in preterm infants born at less than 32 weeks gestation; surfactant and mechanical ventilation have been the standard treatment. However, despite advances in neonatal respiratory care, a considerable number of preterm infants develop chronic lung disease, termed bronchopulmonary dysplasia (BPD), which is associated with neonatal death, prolonged neonatal intensive care stay, and impaired neurodevelopment. High-frequency oscillatory ventilation (HFOV) was developed as a new ventilation technique in the late 1970s. It was expected to result in less BPD and death as a primary model of ventilation compared to conventional ventilation (CV) in the treatment of RDS. However, there is disagreement concerning the advantage of HFOV over CV in the treatment of RDS in preterm infants regarding the prevention of death, BPD, intraventricular hemorrhage, and periventricular leucomalacia in the short term. The purpose of this study was to compare the efficacy and safety of HFOV and CV in preterm infants with severe RDS.

Detailed description

All patients were monitored including blood pressure, heart rate, oxygen saturation, ventilator settings, and arterial blood gases pre- or during mechanical ventilation. PaO2/FIO2 was calculated. After 2 hours ventilation, if PaO2/FIO2 \<200, patients were given rescue surfactant therapy (Curosurf 200mg/kg). A subsequent dose (100mg/kg) was administered when PaO2/FIO2 \<200 12 hours after the previous dose. Surfactant was administered with use of in-line catheters. Suctioning was performed 6 hours after surfactant administration, except for some patients needed suction soon, with use of an in-line suction catheter. Ventilation continued during the administration of surfactant and suctioning.

Interventions

DEVICEmechanical ventilation (SLE 5000, Servo-i-Maquet)

Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.

Sponsors

Zhengzhou Children's Hospital, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 24 Hours
Healthy volunteers
No

Inclusion criteria

1. Preterm infants admitted to the NICU with gestational age \<32 weeks, birth weight \<1500g and less than 24 hours of age 2. Who developed RDS requiring mechanical ventilation 3. Presented a partial pressure of oxygen (PaO2): fraction of inspired oxygen (FIO2) ratio \<200 4. Radiograph criteria of severe RDS

Exclusion criteria

1. Infants with genetic metabolic diseases 2. Congenital abnormalities 3. Pneumothorax 4. Grade III-IV intracranial hemorrhage

Design outcomes

Primary

MeasureTime frameDescription
Incidence of bronchopulmonary dysplasiadefined as requirement of oxygen at 36 weeks of postmenstrual ageTo count the number of patients with bronchopulmonary dysplasia at 36 weeks of postmenstrual age.

Secondary

MeasureTime frameDescription
duration of mechanical ventilationnumber of days on mechanical ventilation after birth to 36weeks of postmenstrual ageTo calculate how many days of the newborn baby with mechanical ventilation either HFOV or CV at 36 weeks postmenstrual age.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026